Treating hepatitis C virus infection in active substance users

Clinical Infectious Diseases

Volumn 40, Issue SUPPL. 5, 2005, Pages

  Sylvestre, Diana L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; DIAMORPHINE; METHADONE; RIBAVIRIN; VIRUS RNA;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HEROIN DEPENDENCE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OUTPATIENT CARE; PATIENT PARTICIPATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUBSTANCE ABUSE; VIRUS DETECTION;

FEMALE; HEPATITIS C; HUMANS; MALE; MENTAL DISORDERS; METHADONE; MIDDLE AGED; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 16844382462     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427447     Document Type: Conference Paper

References (9)

1. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(Suppl 1):S6-10.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
4. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
5. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-93.
6. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002; 8:45-9.
7. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67:117-23.
8. McHutchison JG, Gordon SC, Shiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-92.
9. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-32.